



an Open Access Journal by MDPI

New Approaches to Vaccine Development and Delivery

Guest Editor:

Dr. Antonio Carlos de Freitas

Laboratory of Molecular Studies
and Experimental Therapy,
Department of Genetics, Federal
University of Pernambuco,
Recife, Brazil

Deadline for manuscript
submissions:

closed (31 October 2025)

Message from the Guest Editor

Dear Colleagues,

The COVID-19 pandemic created an opportunity for innovation in the development, evaluation, and speed of vaccine development and evaluation. Contemporary strategies such as nucleic acid vaccines, developing vaccines based on whole cells, exploring new vaccine delivery methods, and creating shelf-stable formulas have made it possible to approach prophylactic and therapeutic vaccines in new ways. In this Special Issue, we will examine new advances in the field of vaccines and delivery systems that could help propel the field forward beyond its previous limits.

Dr. Antonio Carlos de Freitas

Guest Editor



mdpi.com/si/198440

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)